Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2162219 | Seminars in Oncology | 2012 | 17 Pages |
Abstract
Therapeutic cancer vaccines are a unique treatment modality in that they initiate a dynamic process of activating the host immune system, which can then be exploited by concurrent or subsequent therapies. The addition of immunotherapy to standard-of-care cancer therapies has shown evidence of efficacy in preclinical models and in the clinical setting. This review examines the preclinical and clinical interactions between vaccine-mediated tumor-specific immune responses and local radiation, systemic chemotherapy, or select small molecule inhibitors, as well as the potential synergy between these modalities.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
James W. Hodge, Andressa Ardiani, Benedetto Farsaci, Anna R. Kwilas, Sofia R. Gameiro,